Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Raptor Phar Form 4	maceutical Corp										
February 11	. 2014										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB APPROVAL				
Check th if no lon subject to Section 2 Form 4 of Form 5 obligation may con <i>See</i> Instr 1(b).	uis box ger o 16. or Filed pur ns tinue. uction	IENT OF rsuant to S a) of the F	Wa F CHAN Section 1 Public U	NGES IN SECUR 16(a) of th	, D.C. 20 BENEF RITIES le Securit ding Cor	ICIAL (ties Exchnpany Ac	DWNERSHIP OF ange Act of 1934, ct of 1935 or Section	OMB Number: Expires: Estimated burden hou response	urs per		
1. Name and Address of Reporting Person <u>*</u> Erbez Georgia			2. Issuer Name and Ticker or Trading Symbol Raptor Pharmaceutical Corp [RPTP]				5. Relationship of Reporting Person(s) to Issuer[(Check all applicable)				
(Last) (First) (Middle) C/O RAPTOR PHARMACEUTICAL CORP., 5 HAMILTON LANDING, SUITE 160			3. Date of Earliest Transaction (Month/Day/Year) 02/07/2014				Director X Officer (give below)	Director 10% Owner X Officer (give title Other (specify			
(Street) NOVATO, CA 94949			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tab	la I Non I	Dorivotivo	Socuritios	Acquired, Disposed of	or Bonoficio	lly Ownod		
1.Title of 2. Transaction Date 2A. Deen Security (Month/Day/Year) Execution (Instr. 3) any (Month/Day/Year)		Execution	ed 3. 4 Date, if Transaction/ Code I		4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of 6 Securities F Beneficially (1 Owned (1 Following (1 Reported Transaction(s) (Instr. 3 and 4)	. Ownership orm: Direct D) or Indirect	7. Nature of Indirect		
Reminder: Rep	port on a separate line	for each cla	ass of sec	urities benef	ficially ow	ned directly	y or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 2 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securities (Month/Day/Year) Security or Exercise any Code Securities (Instr. 3 and 4) Price of (Month/Day/Year) (Instr. 8) (Instr. 3) Acquired (A) Derivative or Disposed of Security (D) (Instr. 3, 4, and 5) Code V (A) (D) Date Exercisable Expiration Title Amount Date or Number of Share Stock options Common \$14.74 02/07/2014 83,800 08/07/2014(1) 02/07/2024 83,80 Α Stock (right to buy) **Reporting Owners** Relationships **Reporting Owner Name / Address** Director 10% Owner Officer Other Erbez Georgia C/O RAPTOR PHARMACEUTICAL CORP. Chief Financial Officer 5 HAMILTON LANDING, SUITE 160 **NOVATO, CA 94949 Signatures** /s/ Mark Jones, Raptor Pharmaceutical Corp., 02/11/2014 Attorney-in-Fact **Signature of Reporting Person Date **Explanation of Responses:**

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Stock options vest 6/48ths on the six month anniversary of grant date and 1/48th per month thereafter.

Remarks:

Exhibit 24 - Power of Attorney attached.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.